173 results on '"Carr, Ryan M"'
Search Results
2. Ecoevolutionary biology of pancreatic ductal adenocarcinoma
3. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
4. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma
5. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair
6. Incidence and Effect Duration of Immune Checkpoint Inhibitor-Related Pancreas Adverse Events.
7. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis
8. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia
9. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination
10. The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex
11. Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients
12. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
13. Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis
14. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms
15. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients
16. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
17. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL
18. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia
19. How Accurate Are We in Detecting Biceps Tendinopathy?
20. Toward personalized TGFβ inhibition for pancreatic cancer
21. Correction: E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis
22. Arthroscopic glenoid retrieval in failed TSA: Search and rescue
23. Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers
24. Longitudinal Single Cell Multiomic Analysis of a Patient with GATA2 Haploinsufficiency with ASXL1 Mutant Clonal Hematopoiesis
25. Abstract B002: Modeling evolutionary therapy for GI malignancies
26. Su1171 UTILIZATION, ACTIONABLE OUTCOMES AND CLINICAL TRIAL ELIGIBILITY OF UNIVERSAL PANCREAS ADENOCARCINOMA GERMLINE AND TUMOR SOMATIC TESTING IN CLINICAL PRACTICE
27. Pancreatic cancer microenvironment, to target or not to target?
28. Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer
29. Tu1420 INCIDENCE AND EFFECT DURATION OF IMMUNE CHECKPOINT INHIBITOR RELATED PANCREAS ADVERSE EVENTS
30. Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia
31. ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility
32. GLI1/GLI2 functional interplay is required to control Hedgehog/GLI targets gene expression
33. It Takes a Village to Overcome KRAS Dependence in Pancreatic Cancer
34. Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients
35. Indoleamine 2,3-dioxygenase-1 expressing aggregate bone marrow dendritic cell populations are associated with systemic T-cell compartment changes in chronic myelomonocytic leukemia
36. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients
37. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia
38. RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis
39. Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures
40. Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia
41. Epigenomic Determinants of Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia
42. Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
43. Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients
44. Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms
45. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients
46. Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study
47. Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia
48. LSD1, a double-edged sword, confers dynamic chromatin regulation but commonly promotes aberrant cell growth
49. Molecular Modeling and Functional Analysis of Exome Sequencing–Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma
50. Spectrum of abnormalities and clonal transformation in germline RUNX1familial platelet disorder and a genomic comparative analysis with somatic RUNX1mutations in MDS/MPN overlap neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.